News

November 1, 2016

Parnell Pharmaceuticals Holdings Ltd Announces Financial Results for the Nine-Month Period Ended September 30, 2016

Overland Park, Kansas. (November 2, 2016) — Parnell Pharmaceuticals Holdings Ltd (NASDAQ: PARN), a fully integrated, commercial-stage pharmaceutical company focused on developing, manufacturing and marketing innovative animal health solutions, today announced financial results for the first nine months of 2016 including; strong revenue growth of 62% to $13.8 million, promising results from studies for Zydax for cats, PAR121 and PAR122 as well as the launch of Reviderm™ and agreement of terms on a new $US20 million debt facility.

Click here to view the entire report

###

April 22, 2016

Parnell Pharmaceuticals Holdings Ltd Announces First Quarter Business Update

Parnell continues to grow rapidly with revenue increasing 43% for the three months ended March 31, 2016

OVERLAND PARK, Kan., April 22, 2016 (GLOBE NEWSWIRE) — Parnell Pharmaceuticals Holdings Ltd (NASDAQ:PARN), a fully integrated, commercial-stage pharmaceutical company focused on developing, manufacturing and marketing innovative animal health solutions, today announced business results for the first quarter of 2016 including strong revenue growth of 43%, the conclusion of negotiations on a contract manufacturing agreement with a major multi-national, the upcoming launch of two new products; Luminous™ and Reviderm™ for the companion animal market and receipt of the US Food and Drug Administration, (FDA)’s responses for the two remaining Technical Sections for Zydax for dogs in the US.

Click here to view the entire report

###

February 24, 2016

Parnell Pharmaceuticals Holdings Ltd Announces Financial Results for the Year Ended December 31, 2015

Strong Growth in the U.S. Market Drives Revenue 58% Higher to $13.2 Million for the Year Ended December 31, 2015

OVERLAND PARK, Kan., Feb. 24, 2016 (GLOBE NEWSWIRE) — Parnell Pharmaceuticals Holdings Ltd (NASDAQ:PARN), a fully integrated, commercial stage pharmaceutical company focused on developing, manufacturing and marketing innovative animal health solutions, today announced financial results for the year ended December 31, 2015.

Click here to view the entire report

###

January 20, 2016 

UPDATE – Parnell Pharmaceuticals Holdings Ltd. Announces Agreement with Lincoln Park Capital Fund to Purchase Ordinary Shares

OVERLAND PARK, Kansas, Jan. 20, 2016 (GLOBE NEWSWIRE) — Parnell Pharmaceuticals Holdings Ltd. (“Parnell” or “Company”) (NASDAQ:PARN), a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions, today announced that it has entered into a share purchase agreement with Lincoln Park Capital Fund, LLC, a Chicago-based institutional investor (“Lincoln Park”). The agreement is structured as an equity commitment and enables Parnell to elect entirely at its discretion to sell up to 35,000 shares on any one day to Lincoln Park and under certain circumstances can elect to sell up to 55,000 shares on any one day.

Click here to view the entire report

###

December 20, 2015 

Parnell on Bloomberg and Fox Business News

Rob Joseph, Parnell CEO, talked about Parnell’s focus on delivering innovative solutions to unmet animal health needs in the $70 Billion dollar pet market.

– See video at: http://www.b-tv.com/parnell-pharmaceuticals-ceo-clip/

Click here to view the entire report

###

December 17, 2015 

Parnell Appoints Ellen B. Richstone and Dr. David K. Rosen to the Board of Directors

Appointments Increase the Board to Six Members, Three of Whom Are Independent

OVERLAND PARK, Kansas, Dec. 17, 2015 (GLOBE NEWSWIRE) — Parnell Pharmaceuticals Holdings Ltd (Nasdaq:PARN), a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions, today announced the appointment of Ellen B. Richstone and Dr. David K. Rosen to its Board of Directors. The appointments increase the Board to six directors, and the number of independent directors to three.

Click here to view the entire report

###

November 18, 2015 

Parnell Volunteers with Hearts 4 Heroes & Helped Provide Canine Training in KC for Veterans with PTSD

H4HUS (Hearts for Heroes), a non-profit organization that helps military veterans re-acclimate to life at home through participation in therapeutic canine and equine programs, conducted three days of Canine Handling Immersion training for veterans Nov. 16 through 18 in Kansas City.

Click here to view the entire report

###

November 10, 2015 

H4HUS to Provide Canine Training in Kansas City for Veterans with PTSD

BEDFORD, NY | Nov. 10, 2015 | DMG Bizwire — H4HUS (Hearts for Heroes), a non-profit organization that helps military veterans re-acclimate to life at home through participation in therapeutic canine and equine programs, will conduct three days of Canine Handling Immersion training for veterans Nov. 16 through 19 in Kansas City.

Click here to view the entire report

###

October 21, 2015 

Parnell Pharmaceuticals Holdings Ltd Announces Third Quarter Business Results

Parnell Continues to Grow Rapidly With Revenue Increasing 55% for the Nine Months Ended September 30, 2015

OVERLAND PARK, Kansas, Oct. 21, 2015 (GLOBE NEWSWIRE) — Parnell Pharmaceuticals Holdings Ltd (NASDAQ:PARN), a fully integrated, commercial-stage pharmaceutical company focused on developing, manufacturing and marketing innovative animal health solutions, today announced business results for the third quarter of 2015 and nine months ended September 30, 2015.

Click here to view the entire report

###

October 9, 2015 

Parnell to Report Financial Results for the Nine Months Ended September 30, 2015 on October 21, 2015

OVERLAND PARK, Kansas, Oct. 9, 2015 (GLOBE NEWSWIRE) — Parnell Pharmaceuticals Holdings Ltd. (NASDAQ:PARN), a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions, announced today that on October 21, 2015 at 7:00 a.m. ET it will report financial results for the nine-month period ended September 30, 2015.

Click here to view the entire report

###

Parnell Pharmaceuticals Holdings Ltd Restructures Board

OVERLAND PARK, Kansas, Oct. 9, 2015 (GLOBE NEWSWIRE) — Parnell Pharmaceuticals Holdings Ltd (NASDAQ:PARN), a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions, today announced changes in the structure of its Board of Directors including the engagement of Egon Zhender to identify and assist in the appointment of additional high caliber independent directors and at the same time, Parnell announced that it has accepted the resignation of Thomas Duley, Phyllis Gardner, and David Greenwood as directors of the Company effective Monday, September 28, 2015.

Click here to view the entire report

###

August 2015

Parnell Pharmaceuticals Holdings Ltd Announces Financial Results for the Six-Month Period Ended June 30, 2015

Parnell Pharmaceuticals Holdings Ltd (NASDAQ:PARN), a fully integrated, commercial stage pharmaceutical company focused on developing, manufacturing and marketing innovative animal health solutions, today announced financial results for the six-month period ended June 30, 2015.

Click here to view the entire report

###

Parnell Appoints Peter A. Croden to Board of Directors

Parnell Pharmaceuticals Holdings Ltd (Nasdaq: PARN), a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions, today announced the appointment of Peter A. Croden to its Board of Directors.  The appointment increases the Board to seven directors, and the number of independent directors to four. Click here to view the entire report

###

July 2015 

Parnell to Report Financial Results for the Six Months Ended June. 

Parnell Pharmaceuticals Holdings Ltd. (NASDAQ:PARN), a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions, announced today that on August 11, 2015 at 7:00 a.m. ET it will report financial results for the six-month period ended June 30, 2015. Click here to view the entire report

###

June 2015

Parnell Pharmaceuticals Holdings Ltd Investor Day Highlights

Parnell Pharmaceuticals Holdings Ltd (Nasdaq:PARN), a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions, released highlights from its inaugural Investor Day held today in New York City. Click here to view the entire report

###

Parnell Pharmaceuticals Holdings Ltd Announces Positive Top-Line Pivotal Trial Results for Zydax(R), Disease-Modifying Osteoarthritis Drug in Dogs

Parnell Pharmaceuticals Holdings Ltd (Nasdaq:PARN), a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions, today announced that Zydax, Parnell’s osteoarthritis (OA) therapeutic being developed for dogs and horses, demonstrated a significant improvement in clinical signs of osteoarthritis in dogs in a pivotal clinical efficacy trial. Click here to view the entire report

###

Parnell Pharmaceuticals Holdings Ltd Announces $11 Million Secured Term Loan Facility

Parnell Pharmaceuticals Holdings Ltd (Nasdaq:PARN), a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions, today announced that it has entered into a non-dilutive $US11 million term loan agreement with MidCap Financial. Click here to view the entire report

###

Parnell Pharmaceuticals Holdings Ltd to Host Inaugural Investor Day on June 18, 2015

Parnell Pharmaceuticals Holdings Ltd. (Nasdaq:PARN), a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions, today announced that the company will hold its first Investor Day event for the institutional investment and research analyst community on Thursday, June 18th, 2015 in New York City. Click here to view the entire report

###

April 2015

Parnell Pharmaceuticals Holdings Ltd Announces First Quarter Business Results

Parnell Pharmaceuticals Holdings Ltd. (Nasdaq:PARN), a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions, today announced business results for the first quarter 2015. Click here to view the entire report

###

April 2015

Parnell to Discuss First Quarter Business Performance on April 22, 2015

Parnell Pharmaceuticals Holdings Ltd. (Nasdaq:PARN), a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions, today announced that the Company will report first quarter business results on April 22, 2015. As a Foreign Private Issuer, Parnell is only required to report financial results each half-year. Going forward, the Company intends to provide quarterly updates to investors for the interim quarters. Click here to view the entire report

###

March 2015

Parnell Presents at Jefferies 2015 Animal Health Summit

Parnell Pharmaceuticals Holdings Ltd (Nasdaq:PARN), a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions, today announced that Robert Joseph, President and Chief Executive Officer, will be presenting at the Jefferies 2015 Animal Health Summit in New York on Thursday, March 26, 2015 at 11:40 AM ET. Click here to view the entire report

###

February 2015

Parnell Announces Financial Results for the Six-Month Period Ended December 31, 2014

Parnell Pharmaceuticals Holdings Ltd (Nasdaq:PARN), a fully integrated, commercial stage pharmaceutical company focused on developing, manufacturing and marketing innovative animal health solutions, today announced financial results for the six-month period ended December 31, 2014. Click here to view the entire report

###

February 2015

Parnell to Report Financial Results for the Fiscal Period Ended December 31, 2014 on February 25, 2015

Parnell Pharmaceuticals Holdings Ltd. (Nasdaq:PARN), a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions, announced today that on February 25, 2015 at 7:00 am ET it will report financial results for the six-month period ended December 31, 2014. The six-month reporting period is part of a previously announced transition to reporting financial results on a calendar year basis (previously June 30 year-end). Click here to view the entire report

###

November 2014

Parnell Present at the Jefferies Global London Healthcare Conference Nov 19th, 2014

Parnell CEO Robert Joseph presents Parnell’s pipeline at the Jefferies 2014 Global Healthcare Conference in London. The event saw over 100 leading global pharmaceutical and biotech companies present to over 850 attendees from top VC and investment companies. See Jefferies presentation here

###

September 2014

Parnell Reports Fiscal Year 2014 Financial Results September 15, 2014

“FY2014 was a transformational year for Parnell with the completion of our initial public offering, strong sales growth in our established markets and the impressive expansion of our new U.S. commercial business. We were also pleased to achieve a number of important milestones in the development of our high potential pipeline products and our innovative digital technologies,” said Robert Joseph, President and Chief Executive Officer of Parnell Pharmaceuticals Holdings Ltd. “

Click here to view the entire report

###

Parnell Moves Continents to Bring Biotech Offering to Fruition

“Parnell Moves Continents to bring Biotech Offering to Fruition.”  Animal Pharm, September 11, 2014.

Click here to view the entire article

###

Parnell to Report Fiscal Year 2014 Financial Results September 15, 2014

Overland Park, Kansas, (September 10, 2014)— Parnell Pharmaceuticals Holdings Ltd. (NASDAQ: PARN), a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions, announced today that it will report full-year financial results on September 15, 2014 at 4:00 pm ET. Parnell To Report Full-Year Financial Results 

###

Parnell Appoints U.S.-based Independent Directors Phyllis Gardner, M.D., and David L. Greenwood to its Board of Directors

Australian-based Directors Andrew Want and Peter Molloy Step Down

Overland Park, Kansas, (September 8, 2014)— Parnell Pharmaceuticals Holdings Ltd today announced that it had appointed U.S. based Phyllis Gardner, MD, and David L. Greenwood to its Board of Directors, effective immediately.  Dr. Gardner has over 35 years of experience in academia, medicine and the healthcare industry.  Mr. Greenwood brings substantial expertise in financing pharmaceutical and biotechnology companies. Parnell Appoints two new U.S. based Independent Directors to the Board

###

Parnell Announces Results from the Successful Efficacy Study for Zydax®

Zydax effective in reducing osteoarthritis pain and interference in dogs in large-scale pilot efficacy study

Overland Park, Kansas, (September 3, 2014)— Parnell Pharmaceuticals Holdings Ltd today announced the results from a successful, large-scale efficacy study of Zydax, for the treatment of the clinical signs of canine osteoarthritis, or OA.  Zydax is intended to stimulate the growth of new cartilage and inhibit cartilage breakdown for the treatment of OA in dogs and horses. Parnell Announces Results from the Successful Efficacy Study

###

August 2014

Parnell Expands Headquarters in Overland Park

Animal health company will create 32 new jobs  

Overland Park, Kans. / (August 26, 2014) – Parnell, an animal health company, has announced that it will expand its headquarters and create 32 new jobs in Overland Park. The company offers pharmaceutical products and technology solutions to enhance the quality of life and performance of animals. “Parnell is very excited to be able to continue its expansion in Kansas with the addition of 32 new jobs and an enlarged facility for our global headquarters,” said Robert Joseph, president and CEO of Parnell. “Our new team members will support our future companion animal product launches and the continued growth of our reproductive hormone portfolio. The support from the Kansas Department of Commerce is testament to the commercial opportunities in the Animal Health Corridor.”

Parnell Expands Headquarters

###

July 2014

Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration

Overland Park, Kans. / (July 22, 2014) — Parnell Pharmaceuticals Holdings Ltd announces the successful licensing of two compounds that will be added to Parnell’s already extensive pipeline through a license agreement with Australian-based CIMTECH Pty Ltd, a biotechnology company. The compounds now known as PAR 121 and PAR 122 have shown promise in bone regeneration and dermal regeneration, respectively. Parnell has received a license to develop the compounds for the veterinary market with the potential to also seek human drug approvals.

Parnell Acquires License

###

“All Together Now:  Whole Herd Synchronization”

Predictable Results with Timed-AI

American Dairymen June 2014

###

June 2014

NASDAQ Welcomes Parnell (NASDAQ: PARN) to The NASDAQ Stock Market

NEW YORK, June 18, 2014 (GLOBE NEWSWIRE) — The NASDAQ OMX Group, Inc. announced that trading of Parnell Pharmaceuticals Holdings Ltd, a veterinary pharmaceutical company focused on developing, manufacturing and commercializing animal health solutions, commenced on The NASDAQ Stock Market on June 18, 2014. NASDAQ Welcomes Parnell

###

May 2014

Parnell Pharmaceuticals Files Registration for Proposed Initial Public Offering

Australian-based company takes first steps to offer shares on NASDAQ Global Market

Sydney, Australia / (May 21, 2014) — Parnell Pharmaceuticals Holdings Pty. Ltd. (Parnell) today announced that it has filed a registration statement on Form F-1 with the Securities and Exchange Commission for a proposed initial public offering of its ordinary shares.

Parnell Files Registration

###

August 2013

“Proven Strategies to Improve Timed Breeding Pregnancy Outcomes 

American Dairymen August 2013

###

 May 2013

The U.S. Food and Drug Administration (FDA) would like to announce there is now an approved product, GONAbreed, a sterile injectable solution of gonadorelin acetate

Daniel G. McChesney, Ph.D. Director, Office of Surveillance and Compliance, FDA notifies Bovine Veterinarians about GONAbreed® (gonadorelin acetate), the first FDA Approved reproduction hormone for synchronizing estrous cycles. FDA – Gonabreed

###

February 2013

Parnell Announces Launch of new Product

Parnell announces the launch of SYNCHRONIZATION PACK™, containing estroPLAN® (cloprostenol sodium) and GONAbreed® (gonadorelin acetate) – the first reproductive hormone ever to be approved by the FDA to synchronize estrous cycles in lactating dairy cows and beef cows. mysynch boxproduct-gonabreed2product-estroplan2 Synchronization Pack Launches

###

August 2009

Parnell Opens World Class Manufacturing Facility 

Parnell launches its new multi-million dollar, world class manufacturing plant and laboratories in Sydney, Australia, to support its growing international business. Parnell-34 Parnell Opening Release
To
Top